EZlife Bio Inc. (abbr. EZlife Bio) is a diagnostics company founded by Dr. Wei Liao. EZlifeBio’s core technology originated from the University of California Los Angeles (UCLA), and has been featured as the cover article in both “Clinical Cancer Research” (2009) and “Respiratory and Critical Care Medicine” (2013) journals. Noninvasive precision tumor gene detection, which EZlifeBio specializes in, has been praised by the US government as one of top 10 potentials game-changers in biotech.
The EZlifeBio platform is the world’s first direct detection liquid biopsy instrument. Using a small volume of blood, the EZlifeBio provides fast, convenient and extremely sensitive testing of oncogenic mutations.
- The world's first
- High accuracy measurement
- Direct detection
- World’s leading role
- Fast and convenient process
- The prototype has passed the test
- Automatically completed by the apparatus
- Finalized design by EZlife Bio
10855 Le Conte Ave. Los Angeles, CA 90025